Breakthrough Trial Finds High-Dose Fish Oil Slashes Heart Risks in Dialysis Patients

January 14, 2026

In a major breakthrough for kidney care, a large-scale international clinical trial has revealed that a high-dose daily fish oil supplement significantly reduces the risk of life-threatening cardiovascular events in patients undergoing dialysis.

The findings, stemming from the PISCES trial, were recently presented at the American Society of Nephrology Kidney Week 2025 and published in the prestigious New England Journal of Medicine (NEJM). The study suggests that for a patient population often plagued by heart complications and limited treatment options, a specific regimen of omega-3 fatty acids could offer a powerful new line of defense.

A New Hope for a High-Risk Population

For patients with end-stage kidney disease requiring dialysis, the threat of heart disease is a constant shadow. Cardiovascular complications remain the leading cause of death in this group, yet many standard heart medications do not offer the same level of protection for dialysis patients as they do for the general public.

The PISCES trial (Prevention of Cardiovascular Events in Patients with End-Stage Renal Disease with n-3 Fatty Acids) sought to change that. Researchers followed 1,228 patients (average age 64) across 26 sites in Australia and Canada. All participants were receiving dialysis and had been doing so for an average of nearly four years.

The results were described by experts as “striking.” Patients who took four grams of high-purity fish oil daily experienced a 43% reduction in major cardiovascular events—including heart attacks, strokes, cardiac deaths, and vascular-related amputations—compared to those who took a placebo.

Why Fish Oil? Understanding the Mechanism

The supplement used in the trial contained concentrated amounts of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), the two primary omega-3 fatty acids found in cold-water fish.

“Patients on dialysis have extremely high cardiovascular risk, and very few therapies have been shown to reduce that risk,” said Adjunct Professor Kevan Polkinghorne, a nephrologist at Monash Health who led the Australian arm of the trial. “In a field where many trials have been negative, this is a significant finding.”

Researchers point to several reasons why this specific group saw such a dramatic benefit:

• Correction of Deficiency: Dialysis patients often have the lowest recorded levels of omega-3s in medical literature. Supplementation may simply be restoring these levels to a protective baseline.

• Reduced Inflammation: Omega-3s are known for their anti-inflammatory properties, which can help combat the chronic inflammation common in kidney failure.

• Lipid Management: The supplements may improve “atherogenic” lipids (fats that clog arteries) and reduce oxidative stress.

• Anti-Clotting Effects: There is evidence that high-dose fish oil may reduce the risk of acute blood clots (thrombosis).

“Perhaps one of the effects is that we’re able to bring it up to baseline or even above, and then to allow for those cardioprotective effects,” noted Dr. Charmaine Lok, lead author and physician at the University Health Network in Toronto.

Critical Caveats: Not All Fish Oil is Equal

While the 43% reduction is a landmark statistic, experts urge caution before patients rush to the supplement aisle of their local pharmacy.

Dr. Lok emphasized that the PISCES study used a very high and highly purified dose of polyunsaturated fatty acids (PUFA). “I don’t know that you would have the same effect if you just bought something over the counter,” she warned, noting that many consumer-grade supplements contain lower concentrations or less stable forms of the oil.

Furthermore, Professor Polkinghorne stressed that these results are highly specific. The study focused strictly on patients with kidney failure receiving hemodialysis. There is currently no evidence from this trial to suggest that healthy individuals or those with other conditions would see the same magnitude of benefit from such a high dose.

The Study at a Glance

Expert Perspective: A Shift in Clinical Practice?

External experts see this as a potential turning point in nephrology. For years, the “statin” class of cholesterol drugs, while effective for many, has shown mixed results in reducing mortality specifically for dialysis patients.

“The dialysis population is unique because their heart disease is often driven by factors beyond just cholesterol, such as mineral imbalances and arterial stiffness,” says Dr. Aris Kyriakides, a cardiologist not involved in the study. “Seeing a 43% reduction with a relatively safe intervention like omega-3s is a call to action for clinicians to re-evaluate their supplement protocols.”

However, some researchers remain cautious, noting that high-dose fish oil has been linked in other studies (such as the REDUCE-IT trial) to a slight increase in the risk of atrial fibrillation (an irregular heart rhythm). Monitoring for such side effects will be crucial as this therapy moves toward wider adoption.

What This Means for You

If you or a loved one is currently undergoing dialysis, this research is encouraging but should be discussed with a medical team first.

1. Consult Your Nephrologist: Do not start a high-dose fish oil regimen on your own. High doses can affect blood thinning and interact with other medications.

2. Focus on Quality: If your doctor agrees with the treatment, ensure you are using a medical-grade or highly purified supplement similar to the one used in the trial.

3. Holistic Management: Fish oil is an “add-on” therapy, not a replacement for dialysis, blood pressure medication, or a kidney-friendly diet.

References

• https://www.ndtv.com/health/daily-fish-oil-supplement-reduces-serious-cardiovascular-risks-in-dialysis-patients-finds-study-10742007

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.